Enzychem Lifesciences Corporation (KOSDAQ: 183490)

Enzychem Lifesciences Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	6,805	15,470	7,683	2,784	1,858	2,288
Short-Term Investments	109,489	121,604	185,173	91,803	88,646	43,133
Trading Asset Securities	-	276	-	-	-	-
Cash & Short-Term Investments	116,294	137,350	192,856	94,587	90,504	45,421
Cash Growth	-19.99%	-28.78%	103.89%	4.51%	99.25%	29.71%
Accounts Receivable	8,259	11,625	6,358	5,206	4,186	8,668
Other Receivables	846.82	1,425	3,428	661.09	381.36	585.5
Receivables	24,782	20,207	10,312	5,986	4,676	9,458
Inventory	13,634	14,946	9,794	8,355	9,178	7,847
Prepaid Expenses	151.69	134.77	73.65	169.68	95.17	150.39
Other Current Assets	1,230	1,837	7,277	685.8	546.39	360.36
Total Current Assets	156,092	174,475	220,313	109,783	104,999	63,236
Property, Plant & Equipment	24,393	26,164	23,294	15,431	15,669	14,813
Long-Term Investments	341.42	1,574	476.43	486.51	456.03	4,258
Goodwill	1,480	1,480	-	-	-	-
Other Intangible Assets	3,820	4,371	2,186	6,469	1,968	1,562
Long-Term Deferred Tax Assets	570.71	571.39	-	-	-	-
Long-Term Deferred Charges	-	-	0	-	1.17	9.4
Other Long-Term Assets	2,594	2,859	1,233	884.1	625.98	877.92
Total Assets	189,322	211,546	247,555	133,084	123,802	84,991
Accounts Payable	1,623	6,493	1,496	2,250	867.65	2,738
Accrued Expenses	6.28	10.21	59.78	16.12	15.77	3.92
Short-Term Debt	2,527	2,280	33,750	45,629	4,380	2,314
Current Portion of Long-Term Debt	1,130	1,113	2,492	2,867	1,058	300
Current Portion of Leases	479.71	654.19	344.64	126.7	191.28	177.52
Other Current Liabilities	3,020	3,603	4,142	2,732	3,271	1,966
Total Current Liabilities	8,785	14,154	42,284	53,621	9,784	7,499
Long-Term Debt	2.5	1,025	683.32	3,175	37,120	-
Long-Term Leases	404.31	584.45	509.09	179.98	317.11	298.01
Long-Term Deferred Tax Liabilities	679.93	715.09	-	819.58	2,695	-
Other Long-Term Liabilities	-	0	0	0	-0	1,587
Total Liabilities	10,643	16,919	45,811	58,422	51,320	10,951
Common Stock	42,533	42,533	42,144	4,166	4,124	3,930
Additional Paid-In Capital	108,957	108,431	309,804	194,149	164,219	148,368
Retained Earnings	35,885	41,910	-151,053	-124,665	-95,176	-77,790
Comprehensive Income & Other	129.09	641.6	580.01	822.79	-707.74	-634.63
Total Common Equity	177,535	193,516	201,474	74,472	72,458	73,873
Minority Interest	1,144	1,111	-	-	-	-
Shareholders' Equity	178,679	194,627	201,744	74,662	72,483	74,041
Total Liabilities & Equity	189,322	211,546	247,555	133,084	123,802	84,991
Total Debt	4,543	5,657	37,779	51,977	43,067	3,090
Net Cash (Debt)	111,751	131,693	155,077	42,609	47,437	42,332
Net Cash Growth	-19.76%	-15.08%	263.95%	-10.18%	12.06%	35.90%
Net Cash Per Share	1341.87	1550.62	1967.48	843.86	976.40	902.07
Filing Date Shares Outstanding	79.84	85.07	84.29	49.99	49.48	47.16
Total Common Shares Outstanding	79.84	85.07	84.29	49.99	49.48	47.16
Working Capital	147,307	160,321	178,028	56,163	95,215	55,737
Book Value Per Share	2223.71	2274.90	2390.31	1489.80	1464.30	1566.59
Tangible Book Value	172,236	187,665	199,289	68,003	70,490	72,312
Tangible Book Value Per Share	2157.33	2206.12	2364.38	1360.38	1424.53	1533.47
Land	8,249	8,090	6,249	6,249	6,249	610.91
Buildings	9,883	9,883	9,055	6,092	6,092	6,075
Machinery	21,408	21,252	18,549	14,238	12,790	12,287
Construction In Progress	89	122.75	68.5	194.46	559.02	4,424

Source: S&P Capital IQ. Standard template. Financial Sources.